Chun Elizabeth, Joseph Richard, Pojednic Rachele
Restore Hyper Wellness, Austin, TX, United States.
Department of Statistics, Texas A&M University, College Station, TX, United States.
Interact J Med Res. 2024 Nov 22;13:e60942. doi: 10.2196/60942.
Chronically elevated inflammation is implicated in many conditions, including obesity, metabolic syndrome, and cardiovascular disease, and has been associated with increased mortality risk. Whole-body cryotherapy (W-BC) is a promising modality to treat inflammation with demonstrated benefits for clinical subpopulations including those with arthritis, obesity, and type 2 diabetes. However, it is unclear whether the benefit from W-BC extends to healthy individuals prior to chronic disease-related inflammation. In addition, the long-term durability of W-BC effect is unknown.
This study investigates the inflammatory response to W-BC in healthy adults with a biomarker of inflammation, high-sensitivity C-reactive protein (hsCRP), and clinical biomarkers of metabolism including fasting glucose, hemoglobin A (HbA), low-density lipoprotein (LDL) and high-density lipoprotein (HDL), and triglycerides.
Fifteen individuals (n=9 female) participated in frequent recreational W-BC (3 minutes of cold exposure at -110 ℃) over approximately 9 months and had blood draws at baseline plus follow-up visits. Biomarkers were modeled as linear functions of W-BC sessions received in the month prior to blood draw.
The mean amount of W-BC received was 6.78 (SD 4.26) times per month with the cumulative total ranging from 13 to 157 W-BC sessions over the course of the study. On average, participants completed 1-2 sessions per week throughout the intervention. The number of W-BC sessions were associated with decreased hsCRP (-0.14 mg/L in hsCRP per W-BC session; P<.01) and with durability of up to 9 months. Increased W-BC was also associated with a downward trend in fasting glucose. This trend failed to reach significance at 1 month (-0.73 mg/dL in fasting glucose per W-BC session; P<.10) but was significant for 2- and 3-month windows (P<.05). HbA was increased significantly after 9 months (P<.01); however, the change occurred within normal ranges (difference=0.13% and <5.7%) and was not clinically significant. There was no association between W-BC and LDL cholesterol, HDL cholesterol, or triglycerides (P>.10), although LDL trended lower over the time period examined (P=.07).
These results suggest that W-BC beneficially impacts systemic inflammation by lowering hsCRP levels in healthy individuals and may also have some modulating effect on fasting glucose.
慢性炎症水平升高与多种疾病相关,包括肥胖、代谢综合征和心血管疾病,且与死亡风险增加有关。全身冷冻疗法(W-BC)是一种有前景的治疗炎症的方法,已证明对包括关节炎、肥胖和2型糖尿病患者在内的临床亚群有益。然而,尚不清楚W-BC的益处是否能扩展到与慢性疾病相关炎症之前的健康个体。此外,W-BC效果的长期持续性尚不清楚。
本研究通过炎症生物标志物高敏C反应蛋白(hsCRP)以及代谢临床生物标志物,包括空腹血糖、糖化血红蛋白(HbA)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)和甘油三酯,调查健康成年人对W-BC的炎症反应。
15名个体(9名女性)在约9个月的时间里频繁进行休闲性W-BC(在-110℃下冷暴露3分钟),并在基线及随访时进行血液采集。生物标志物被建模为采血前一个月接受的W-BC疗程的线性函数。
每月接受W-BC的平均次数为6.78次(标准差4.26),在研究过程中累积总数为13至157次W-BC疗程。在整个干预过程中,参与者平均每周完成1-2次疗程。W-BC疗程次数与hsCRP降低相关(每次W-BC疗程hsCRP降低0.14mg/L;P<.01),且持续长达9个月。W-BC次数增加还与空腹血糖呈下降趋势相关。这种趋势在1个月时未达到显著水平(每次W-BC疗程空腹血糖降低0.73mg/dL;P<.10),但在2个月和3个月时显著(P<.05)。9个月后HbA显著升高(P<.01);然而,变化在正常范围内(差异=0.13%且<5.7%),无临床意义。W-BC与LDL胆固醇、HDL胆固醇或甘油三酯之间无关联(P>.10),尽管在研究时间段内LDL有下降趋势(P=.07)。
这些结果表明,W-BC通过降低健康个体的hsCRP水平对全身炎症产生有益影响,并且可能对空腹血糖也有一定的调节作用。